83 related articles for article (PubMed ID: 10655892)
1. Setting up a breast cancer family history clinic.
Saunders C; Vijay V; Stein J; Baum M
Ann R Coll Surg Engl; 1999 Nov; 81(6):393-8. PubMed ID: 10655892
[TBL] [Abstract][Full Text] [Related]
2. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
3. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
[TBL] [Abstract][Full Text] [Related]
4. Hereditary breast-ovarian cancer: clinical findings and medical management.
Marshall M; Solomon S
Plast Surg Nurs; 2007; 27(3):124-7. PubMed ID: 17901820
[TBL] [Abstract][Full Text] [Related]
5. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.
Kuschel B; Lux MP; Goecke TO; Beckmann MW
Eur J Cancer Prev; 2000 Jun; 9(3):139-50. PubMed ID: 10954253
[TBL] [Abstract][Full Text] [Related]
6. Inherited genetic susceptibility to breast cancer.
Chang-Claude J
IARC Sci Publ; 2001; 154():177-90. PubMed ID: 11220657
[TBL] [Abstract][Full Text] [Related]
7. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
Rebbeck TR; Friebel T; Lynch HT; Neuhausen SL; van 't Veer L; Garber JE; Evans GR; Narod SA; Isaacs C; Matloff E; Daly MB; Olopade OI; Weber BL
J Clin Oncol; 2004 Mar; 22(6):1055-62. PubMed ID: 14981104
[TBL] [Abstract][Full Text] [Related]
8. [Clinical and molecular diagnosis of inherited breast-ovarian cancer].
Chompret A
J Gynecol Obstet Biol Reprod (Paris); 2003 Apr; 32(2):101-19. PubMed ID: 12717301
[TBL] [Abstract][Full Text] [Related]
9. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Offit K; Foulkes W; Robson ME; Wacholder S; Eng CM; Karp SE; Begg CB
Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):467-73. PubMed ID: 11352856
[TBL] [Abstract][Full Text] [Related]
10. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
11. Establishing a family risk assessment clinic for breast cancer.
Mulsow J; Lee J; Dempsey C; Rothwell J; Geraghty JG
Breast J; 2009; 15 Suppl 1():S33-8. PubMed ID: 19775328
[TBL] [Abstract][Full Text] [Related]
12. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome.
Roukos DH; Briasoulis E
Nat Clin Pract Oncol; 2007 Oct; 4(10):578-90. PubMed ID: 17898808
[TBL] [Abstract][Full Text] [Related]
13. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
Adem C; Reynolds C; Soderberg CL; Slezak JM; McDonnell SK; Sebo TJ; Schaid DJ; Myers JL; Sellers TA; Hartmann LC; Jenkins RB
Cancer; 2003 Jan; 97(1):1-11. PubMed ID: 12491499
[TBL] [Abstract][Full Text] [Related]
14. Validation of a tool for identifying women at high risk for hereditary breast cancer in population-based screening.
Hoskins KF; Zwaagstra A; Ranz M
Cancer; 2006 Oct; 107(8):1769-76. PubMed ID: 16967460
[TBL] [Abstract][Full Text] [Related]
15. Psychosocial issues following a positive result of genetic testing for BRCA1 and BRCA2 mutations: findings from a focus group and a needs-assessment survey.
Di Prospero LS; Seminsky M; Honeyford J; Doan B; Franssen E; Meschino W; Chart P; Warner E
CMAJ; 2001 Apr; 164(7):1005-9. PubMed ID: 11314429
[TBL] [Abstract][Full Text] [Related]
16. Hereditary ovarian cancer--assessing risk and prevention strategies.
Pavelka JC; Li AJ; Karlan BY
Obstet Gynecol Clin North Am; 2007 Dec; 34(4):651-65, vii-viii. PubMed ID: 18061862
[TBL] [Abstract][Full Text] [Related]
17. Population-based study of changing breast cancer risk in Icelandic BRCA2 mutation carriers, 1920-2000.
Tryggvadottir L; Sigvaldason H; Olafsdottir GH; Jonasson JG; Jonsson T; Tulinius H; Eyfjörd JE
J Natl Cancer Inst; 2006 Jan; 98(2):116-22. PubMed ID: 16418514
[TBL] [Abstract][Full Text] [Related]
18. [Genetic test and prophylactic treatment in breast cancer families].
Miyoshi Y; Noguchi S
Gan To Kagaku Ryoho; 2002 Apr; 29(4):512-22. PubMed ID: 11977534
[TBL] [Abstract][Full Text] [Related]
19. Screening and follow-up of the patient at high risk for breast cancer.
Willey SC; Cocilovo C
Obstet Gynecol; 2007 Dec; 110(6):1404-16. PubMed ID: 18055740
[TBL] [Abstract][Full Text] [Related]
20. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
